Gene therapies have been a point of discussion during the last several years as a potential curative option for a variety of disease indications. While mainly still in preclinical stages, gene therapy aims to treat or alleviate a disease by genetically modifying the cells of a patient.

Currently, small biotechs are leading R&D efforts on a variety of cardiovascular and metabolic disorder (CVMD) gene therapies. Despite investment in CVMD gene therapies, the majority of the candidates are still in early R&D stages, whereas several CVMD gene therapies are already in Phase II or Phase III clinical trials.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to GlobalData, within the entire cardiovascular and metabolic disorder (CVMD) space, the current gene therapy pipeline features approximately 13 candidates that are in Phase I, II, or III of clinical development. As seen in Figure 1, there are three gene therapies that have reached Phase III trials: AnGes MG’s Collategene, Angionetics’ Generx, and ViroMed’s donaperminogene seltoplasmid.

Of the pipeline CVMD gene therapies, the majority of them target cardiovascular indications, such as coronary artery disease, peripheral artery disease, critical limb ischemia, and systolic heart failure, indicating the immense opportunity for biotech companies to pursue drug candidates that target metabolic disorders.

Key opinion leaders (KOLs) interviewed by GlobalData are anticipating big pharma companies to partner with these smaller biotech companies to enhance the development of gene therapy candidates within the next decade.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.